from pptx import Presentation
from pptx.util import Inches, Pt, Emu
from pptx.dml.color import RGBColor
from pptx.enum.text import PP_ALIGN, MSO_ANCHOR
from io import BytesIO

prs = Presentation()
prs.slide_width = Inches(13.333)
prs.slide_height = Inches(7.5)

FONT_NAME = "Times New Roman"
FONT_SIZE = Pt(23)
TITLE_SIZE = Pt(32)
SUBTITLE_SIZE = Pt(20)

BG_COLOR = RGBColor(0xFF, 0xFF, 0xFF)       # white background
TITLE_COLOR = RGBColor(0x1A, 0x3A, 0x5C)    # dark navy
TEXT_COLOR = RGBColor(0x22, 0x22, 0x22)     # near black
ACCENT_COLOR = RGBColor(0x1A, 0x3A, 0x5C)  # same navy for accent bar
NUM_COLOR = RGBColor(0x88, 0x88, 0x88)      # grey for slide numbers

TOTAL_SLIDES = 7  # will be updated after we count

def set_bg(slide, color):
    from pptx.oxml.ns import qn
    from lxml import etree
    bg = slide.background
    fill = bg.fill
    fill.solid()
    fill.fore_color.rgb = color

def add_accent_bar(slide, color=ACCENT_COLOR):
    # Top accent bar
    bar = slide.shapes.add_shape(
        1,  # MSO_SHAPE_TYPE.RECTANGLE
        Inches(0), Inches(0),
        Inches(13.333), Inches(0.12)
    )
    bar.fill.solid()
    bar.fill.fore_color.rgb = color
    bar.line.fill.background()

def add_bottom_bar(slide, color=ACCENT_COLOR):
    bar = slide.shapes.add_shape(
        1,
        Inches(0), Inches(7.38),
        Inches(13.333), Inches(0.12)
    )
    bar.fill.solid()
    bar.fill.fore_color.rgb = color
    bar.line.fill.background()

def add_slide_number(slide, number, total):
    tb = slide.shapes.add_textbox(Inches(11.8), Inches(7.1), Inches(1.4), Inches(0.35))
    tf = tb.text_frame
    p = tf.paragraphs[0]
    p.alignment = PP_ALIGN.RIGHT
    run = p.add_run()
    run.text = f"{number} / {total}"
    run.font.name = FONT_NAME
    run.font.size = Pt(13)
    run.font.color.rgb = NUM_COLOR

def add_title_box(slide, title_text, top=Inches(0.18), width=Inches(13.333), height=Inches(1.1)):
    tb = slide.shapes.add_textbox(Inches(0), top, width, height)
    tf = tb.text_frame
    tf.word_wrap = True
    tf.margin_left = Inches(0.5)
    tf.margin_right = Inches(0.5)
    tf.margin_top = Inches(0.05)
    tf.margin_bottom = 0
    p = tf.paragraphs[0]
    p.alignment = PP_ALIGN.CENTER
    run = p.add_run()
    run.text = title_text
    run.font.name = FONT_NAME
    run.font.size = TITLE_SIZE
    run.font.bold = True
    run.font.color.rgb = TITLE_COLOR

def add_content_box(slide, bullets, top=Inches(1.5), left=Inches(0.7), width=Inches(11.9), height=Inches(5.5)):
    tb = slide.shapes.add_textbox(left, top, width, height)
    tf = tb.text_frame
    tf.word_wrap = True
    tf.margin_left = Inches(0.1)
    tf.margin_right = Inches(0.1)
    tf.margin_top = Inches(0.1)

    for i, bullet in enumerate(bullets):
        if i == 0:
            p = tf.paragraphs[0]
        else:
            p = tf.add_paragraph()
        p.space_before = Pt(8)
        p.space_after = Pt(4)
        run = p.add_run()
        run.text = f"• {bullet}"
        run.font.name = FONT_NAME
        run.font.size = FONT_SIZE
        run.font.color.rgb = TEXT_COLOR

# ---------------------------------------------------------------
# SLIDES DATA
# ---------------------------------------------------------------

slides_data = [
    # Slide 1 - Title Slide
    {
        "type": "title",
        "title": "Vaccine for Herpes Zoster",
        "subtitle": "Q11.10 — Immunosuppression",
        "total_label": True,
    },
    # Slide 2 - Background & Burden
    {
        "type": "content",
        "title": "Background: Herpes Zoster (HZ)",
        "bullets": [
            "HZ (shingles) is caused by reactivation of varicella-zoster virus (VZV) in dorsal root ganglia.",
            "Incidence among unvaccinated individuals: 2.15 to 4.05 cases / 1000 person-years.",
            "Post-herpetic neuralgia (PHN) is the most common complication, especially in the elderly.",
            "Vaccination reduces both HZ incidence and severity of PHN.",
        ],
    },
    # Slide 3 - Zostavax Overview
    {
        "type": "content",
        "title": "Zostavax (Zoster Vaccine Live Attenuated)",
        "bullets": [
            "First FDA-approved vaccine for HZ prevention (2006); initially for individuals ≥60 years.",
            "Expanded in 2011 for use in adults aged 50–59 years.",
            "Lyophilized preparation of the Oka/Merck strain of live-attenuated VZV.",
            "Mechanism: Boosts cell-mediated immunity to suppress VZV reactivation.",
        ],
    },
    # Slide 4 - Zostavax Efficacy
    {
        "type": "content",
        "title": "Zostavax — Clinical Efficacy",
        "bullets": [
            "Phase III Shingles Prevention Study: 38,546 adults aged ≥60 years.",
            "Reduced HZ incidence by 51% compared to placebo.",
            "Vaccinated individuals who still developed HZ had less pain and discomfort.",
            "Lower incidence of PHN in vaccinated patients vs. placebo recipients.",
        ],
    },
    # Slide 5 - Shingrix Overview
    {
        "type": "content",
        "title": "Shingrix (Zoster Vaccine Recombinant)",
        "bullets": [
            "FDA-approved in 2017 for adults ≥50 years; recommended by ACIP over Zostavax.",
            "Lyophilized recombinant vaccine containing VZV glycoprotein E + AS01B adjuvant system.",
            "Phase III RCT (15,411 adults ≥50 yrs): 97% efficacy against HZ across all age groups.",
            "Efficacy sustained over 3-year follow-up; ACIP recommends it even after prior Zostavax.",
        ],
    },
    # Slide 6 - Shingrix vs Zostavax & Immunosuppression
    {
        "type": "content",
        "title": "Shingrix vs. Zostavax & Immunosuppression",
        "bullets": [
            "Shingrix preferred over Zostavax; suitable for those previously vaccinated with Zostavax.",
            "Live-attenuated vaccines (Zostavax) carry risk of reversion to high virulence.",
            "Recombinant vaccines (Shingrix) do NOT carry reversion risk — safer profile.",
            "Shingrix may be suitable for immunocompromised individuals where live vaccines are contraindicated.",
        ],
    },
    # Slide 7 - Key Takeaways
    {
        "type": "content",
        "title": "Key Takeaways",
        "bullets": [
            "Two vaccines available: Zostavax (live-attenuated, 2006) and Shingrix (recombinant, 2017).",
            "Shingrix shows superior efficacy (97% vs. 51%) and is the current ACIP-preferred vaccine.",
            "Elderly and immunosuppressed individuals benefit most from HZ vaccination.",
            "Recombinant vaccines are preferred in immunosuppressed patients due to absence of reversion risk.",
        ],
    },
]

TOTAL = len(slides_data)  # 7 total slides

blank = prs.slide_layouts[6]

for idx, data in enumerate(slides_data, start=1):
    slide = prs.slides.add_slide(blank)
    set_bg(slide, BG_COLOR)
    add_accent_bar(slide)
    add_bottom_bar(slide)

    if data["type"] == "title":
        # Big title
        tb = slide.shapes.add_textbox(Inches(0.5), Inches(1.8), Inches(12.3), Inches(1.5))
        tf = tb.text_frame
        tf.word_wrap = True
        p = tf.paragraphs[0]
        p.alignment = PP_ALIGN.CENTER
        run = p.add_run()
        run.text = data["title"]
        run.font.name = FONT_NAME
        run.font.size = Pt(40)
        run.font.bold = True
        run.font.color.rgb = TITLE_COLOR

        # Subtitle
        tb2 = slide.shapes.add_textbox(Inches(0.5), Inches(3.45), Inches(12.3), Inches(0.8))
        tf2 = tb2.text_frame
        p2 = tf2.paragraphs[0]
        p2.alignment = PP_ALIGN.CENTER
        run2 = p2.add_run()
        run2.text = data["subtitle"]
        run2.font.name = FONT_NAME
        run2.font.size = Pt(24)
        run2.font.bold = False
        run2.font.color.rgb = RGBColor(0x55, 0x55, 0x55)

        # Divider line under subtitle
        line = slide.shapes.add_shape(
            1,
            Inches(3.5), Inches(4.35),
            Inches(6.333), Inches(0.04)
        )
        line.fill.solid()
        line.fill.fore_color.rgb = ACCENT_COLOR
        line.line.fill.background()

        # Total slides count
        tb3 = slide.shapes.add_textbox(Inches(0.5), Inches(4.6), Inches(12.3), Inches(0.5))
        tf3 = tb3.text_frame
        p3 = tf3.paragraphs[0]
        p3.alignment = PP_ALIGN.CENTER
        run3 = p3.add_run()
        run3.text = f"Total Slides: {TOTAL}"
        run3.font.name = FONT_NAME
        run3.font.size = Pt(18)
        run3.font.color.rgb = NUM_COLOR
        run3.font.italic = True

        # Slide number bottom right
        add_slide_number(slide, idx, TOTAL)

    else:
        add_title_box(slide, data["title"])
        add_content_box(slide, data["bullets"])
        add_slide_number(slide, idx, TOTAL)

output_path = "/tmp/workspace/herpes-zoster-ppt/Herpes_Zoster_Vaccine.pptx"
buf = BytesIO()
prs.save(buf)
with open(output_path, "wb") as f:
    f.write(buf.getvalue())

print(f"Saved to: {output_path}")
print(f"Total slides: {len(prs.slides)}")

from pptx import Presentation
from pptx.util import Inches, Pt
from pptx.dml.color import RGBColor
from pptx.enum.text import PP_ALIGN
from io import BytesIO

# ── Design tokens ──────────────────────────────────────────────
FONT          = "Times New Roman"
BODY_PT       = Pt(23)
TITLE_PT      = Pt(30)
COVER_PT      = Pt(38)
SUBCOVER_PT   = Pt(22)

WHITE         = RGBColor(0xFF, 0xFF, 0xFF)
NAVY          = RGBColor(0x1A, 0x3A, 0x5C)
LIGHT_NAVY    = RGBColor(0xD6, 0xE4, 0xF0)
DARK_TEXT     = RGBColor(0x1A, 0x1A, 0x1A)
GREY          = RGBColor(0x88, 0x88, 0x88)
GOLD          = RGBColor(0xC8, 0xA0, 0x00)

# ── Slide data ─────────────────────────────────────────────────
# Each entry: ("title", [bullet, ...])
# title-slide entry: ("COVER", subtitle)
slides_data = [
    ("COVER", "Q11.10 — Immunosuppression"),

    ("Background: Herpes Zoster (HZ)", [
        "• HZ (shingles): reactivation of latent VZV from dorsal root or cranial nerve ganglia after primary varicella.",
        "• Incidence in unvaccinated: 2.15–4.05 cases / 1000 person-years; rises steeply with age.",
        "• Most feared complication: Post-herpetic Neuralgia (PHN) — persistent neuropathic pain.",
        "• Vaccination is the most effective prevention strategy.",
    ]),

    ("Risk Factors for HZ", [
        "• Advancing age and immunosenescence.",
        "• Immunosuppressive diseases: HIV infection, leukemia, lymphoma, malignancy.",
        "• Organ transplantation and stem cell transplantation.",
        "• Immunosuppressive drugs: corticosteroids, biologics, JAK inhibitors, chemotherapy.",
    ]),

    ("Zostavax — Overview (Live Attenuated)", [
        "• First FDA-approved HZ vaccine (2006); lyophilized Oka/Merck live-attenuated VZV.",
        "• Initially approved for adults ≥60 yrs; expanded to 50–59 yrs in 2011.",
        "• Route: Single 0.65 mL subcutaneous (SC) injection.",
        "• Discontinued or replaced in many countries due to lower efficacy and waning protection.",
    ]),

    ("Zostavax — Efficacy & Limitations", [
        "• Phase III Shingles Prevention Study (38,546 adults ≥60 yrs): reduced HZ incidence by 51%.",
        "• Vaccinated breakthrough cases had less pain and lower PHN incidence vs. placebo.",
        "• Protection declined significantly after 5–8 years.",
        "• Contraindicated in pregnancy, leukemia/lymphoma, AIDS, transplant recipients, high-dose steroids.",
    ]),

    ("Shingrix — Composition & Adjuvant", [
        "• Lyophilized recombinant vaccine: VZV glycoprotein E (gE) + AS01B adjuvant system.",
        "• AS01B adjuvant contains MPL (Monophosphoryl lipid A) and QS-21.",
        "• The adjuvant drives a strong CD4+ T-cell and antibody response.",
        "• Contains NO live virus — safe profile for immunocompromised patients.",
    ]),

    ("Why Glycoprotein E (gE)?", [
        "• Most abundant VZV envelope protein — present on every infected cell.",
        "• Essential for viral replication and cell-to-cell spread.",
        "• Highly immunogenic and antigenically conserved across VZV strains.",
        "• Ideal target antigen for generating neutralising antibodies and T-cell immunity.",
    ]),

    ("Shingrix — Mechanism of Action", [
        "• Administered IM; gE antigen taken up by dendritic cells at injection site.",
        "• Dendritic cells present antigen → activation of CD4+ T lymphocytes.",
        "• Stimulates production of neutralising antibodies against VZV.",
        "• Boosts VZV-specific cell-mediated immunity → prevents reactivation from sensory ganglia.",
    ]),

    ("Shingrix — Vaccine Efficacy", [
        "• ZOE-50 Trial (adults ≥50 yrs): vaccine efficacy ≈ 97% against HZ.",
        "• ZOE-70 Trial (adults ≥70 yrs): efficacy ≈ 90% — protection maintained in older adults.",
        "• Protection against PHN: ≈ 90%; also reduces ophthalmic zoster and disseminated disease.",
        "• Long-term follow-up: protection persists ≥10 years with only modest waning.",
    ]),

    ("Shingrix vs. Zostavax — Comparison", [
        "• Shingrix (RZV): recombinant gE, non-live, IM, 2 doses; Zostavax (ZVL): live Oka strain, SC, single dose.",
        "• Efficacy: Shingrix ≈97% vs. Zostavax ≈51%; ACIP recommends Shingrix over Zostavax.",
        "• Reversion to high virulence: risk exists with live vaccines (ZVL), absent with recombinant (RZV).",
        "• Shingrix preferred even if previously vaccinated with Zostavax (give ≥8 weeks after ZVL).",
    ]),

    ("Schedule, Dosing & Storage", [
        "• Two-dose series: Dose 1 → wait 2–6 months → Dose 2 (0.5 mL IM, deltoid).",
        "• Immunocompromised: second dose may be given after 1–2 months for rapid protection.",
        "• Never administer intradermally, intravenously, or subcutaneously.",
        "• Storage: 2–8°C; do not freeze; protect from light.",
    ]),

    ("Age Recommendations (CDC/ACIP)", [
        "• Routine vaccination: all adults ≥50 years.",
        "• Also recommended: adults ≥19 years who are immunocompromised.",
        "• Previous chickenpox, shingles, or positive VZV antibodies: vaccination still recommended.",
        "• Can be co-administered with influenza, COVID-19, pneumococcal, or RSV vaccines (different sites).",
    ]),

    ("Immunocompromised Patients", [
        "• Recommended in: HIV, leukemia, lymphoma, solid organ transplant, stem cell transplant.",
        "• Also indicated for: patients on biologics, corticosteroids, JAK inhibitors, or chemotherapy.",
        "• Autoimmune diseases receiving immunosuppressants also qualify.",
        "• Non-live vaccine (RZV) — no reversion risk — preferred over ZVL in all immunocompromised individuals.",
    ]),

    ("Dermatology Indications", [
        "• Evaluate for zoster vaccination before/during immunosuppressive therapy in dermatology patients.",
        "• Traditional agents: methotrexate, azathioprine, mycophenolate, cyclophosphamide, cyclosporine, systemic corticosteroids.",
        "• Biologics: TNF-α, IL-17, IL-23, IL-12/23 inhibitors, rituximab; small molecules: JAK inhibitors.",
        "• Conditions: psoriasis, atopic dermatitis, connective tissue diseases, autoimmune blistering diseases.",
    ]),

    ("Effect on PHN & Complications", [
        "• Shingrix markedly reduces incidence and severity of PHN.",
        "• Also reduces: hospitalisation, ophthalmic zoster, disseminated zoster, severe disease.",
        "• Even if breakthrough HZ occurs post-vaccination, disease is milder and shorter.",
        "• Overall burden of HZ-related morbidity substantially lower in vaccinated individuals.",
    ]),

    ("Contraindications & Special Situations", [
        "• Absolute contraindication: severe allergic reaction to any vaccine component.",
        "• Defer vaccination during acute moderate/severe illness; limited data in pregnancy — generally deferred.",
        "• Previous shingles is NOT a contraindication — vaccinate after lesions have crusted and healed.",
        "• Prior Zostavax: administer Shingrix ≥8 weeks later; prior VZV antibodies: vaccinate per age/risk criteria.",
    ]),

    ("Adverse Effects", [
        "• Local (very common): injection-site pain (most frequent), redness, swelling.",
        "• Systemic: fever, fatigue, headache, myalgia, chills, nausea — usually resolve within 2–3 days.",
        "• Rare: hypersensitivity reactions; post-marketing reports of Guillain-Barré syndrome (very low absolute risk).",
        "• Benefits of vaccination far outweigh the rare adverse event risk in all recommended populations.",
    ]),

    ("Key Takeaways", [
        "• Two HZ vaccines: Zostavax (live, 2006, ~51% efficacy) and Shingrix (recombinant, 2017, ~97% efficacy).",
        "• Shingrix is the current globally preferred vaccine; ACIP recommends it for adults ≥50 yrs and immunocompromised ≥19 yrs.",
        "• Recombinant (non-live) formulation is safe for immunocompromised patients and avoids reversion risk.",
        "• Vaccination significantly reduces HZ incidence, PHN, ophthalmic zoster, and hospitalisations.",
    ]),
]

TOTAL = len(slides_data)   # 18

# ── Helpers ────────────────────────────────────────────────────
def set_bg(slide, color=WHITE):
    fill = slide.background.fill
    fill.solid()
    fill.fore_color.rgb = color

def add_rect(slide, left, top, width, height, color, line=False):
    shape = slide.shapes.add_shape(1, left, top, width, height)
    shape.fill.solid()
    shape.fill.fore_color.rgb = color
    if not line:
        shape.line.fill.background()
    return shape

def textbox(slide, left, top, width, height, wrap=True):
    tb = slide.shapes.add_textbox(left, top, width, height)
    tf = tb.text_frame
    tf.word_wrap = wrap
    tf.margin_left  = Inches(0.08)
    tf.margin_right = Inches(0.08)
    tf.margin_top   = Inches(0.05)
    tf.margin_bottom= Inches(0.05)
    return tf

def add_run(para, text, size, bold=False, italic=False, color=DARK_TEXT):
    run = para.add_run()
    run.text = text
    run.font.name  = FONT
    run.font.size  = size
    run.font.bold  = bold
    run.font.italic= italic
    run.font.color.rgb = color
    return run

def slide_number(slide, num, total):
    tf = textbox(slide, Inches(11.6), Inches(7.1), Inches(1.6), Inches(0.35))
    p = tf.paragraphs[0]
    p.alignment = PP_ALIGN.RIGHT
    add_run(p, f"{num}  /  {total}", Pt(13), color=GREY)

# ── Build presentation ─────────────────────────────────────────
prs = Presentation()
prs.slide_width  = Inches(13.333)
prs.slide_height = Inches(7.5)
blank = prs.slide_layouts[6]

for idx, (title, content) in enumerate(slides_data, start=1):
    slide = prs.slides.add_slide(blank)
    set_bg(slide, WHITE)

    if title == "COVER":
        # ── Full navy header band ──
        add_rect(slide, Inches(0), Inches(0), Inches(13.333), Inches(3.2), NAVY)

        # Main title inside header
        tf = textbox(slide, Inches(0.6), Inches(0.55), Inches(12.1), Inches(2.0))
        p = tf.paragraphs[0]
        p.alignment = PP_ALIGN.CENTER
        add_run(p, "Vaccine for Herpes Zoster", COVER_PT, bold=True, color=WHITE)

        # Gold divider
        add_rect(slide, Inches(3.2), Inches(2.85), Inches(6.9), Inches(0.06), GOLD)

        # Subtitle
        tf2 = textbox(slide, Inches(0.6), Inches(3.05), Inches(12.1), Inches(0.7))
        p2 = tf2.paragraphs[0]
        p2.alignment = PP_ALIGN.CENTER
        add_run(p2, content, SUBCOVER_PT, color=NAVY)

        # Total slides
        tf3 = textbox(slide, Inches(0.6), Inches(3.85), Inches(12.1), Inches(0.55))
        p3 = tf3.paragraphs[0]
        p3.alignment = PP_ALIGN.CENTER
        add_run(p3, f"Total Slides: {TOTAL}", Pt(17), italic=True, color=GREY)

        # Bottom bar
        add_rect(slide, Inches(0), Inches(7.38), Inches(13.333), Inches(0.12), NAVY)
        slide_number(slide, idx, TOTAL)

    else:
        # ── Top navy title bar ──
        add_rect(slide, Inches(0), Inches(0), Inches(13.333), Inches(1.18), NAVY)

        # Title text inside bar
        tf = textbox(slide, Inches(0.45), Inches(0.08), Inches(12.4), Inches(1.02))
        p = tf.paragraphs[0]
        p.alignment = PP_ALIGN.LEFT
        add_run(p, title, TITLE_PT, bold=True, color=WHITE)

        # Light background for content area
        add_rect(slide, Inches(0), Inches(1.18), Inches(13.333), Inches(6.2), LIGHT_NAVY)

        # White content card
        add_rect(slide, Inches(0.4), Inches(1.32), Inches(12.53), Inches(5.78), WHITE)

        # Bullets
        tf2 = textbox(slide, Inches(0.65), Inches(1.45), Inches(12.0), Inches(5.5))
        for i, bullet in enumerate(content):
            para = tf2.paragraphs[0] if i == 0 else tf2.add_paragraph()
            para.space_before = Pt(10)
            para.space_after  = Pt(6)
            add_run(para, bullet, BODY_PT, color=DARK_TEXT)

        # Bottom bar
        add_rect(slide, Inches(0), Inches(7.38), Inches(13.333), Inches(0.12), NAVY)
        slide_number(slide, idx, TOTAL)

# ── Save ───────────────────────────────────────────────────────
out = "/tmp/workspace/herpes-zoster-ppt/Herpes_Zoster_Vaccine_Combined.pptx"
buf = BytesIO()
prs.save(buf)
with open(out, "wb") as f:
    f.write(buf.getvalue())

print(f"Saved: {out}")
print(f"Total slides: {len(prs.slides)}")